EP3411068A4 - Bispecific binding proteins for pd-l1 and kdr - Google Patents

Bispecific binding proteins for pd-l1 and kdr Download PDF

Info

Publication number
EP3411068A4
EP3411068A4 EP17748163.7A EP17748163A EP3411068A4 EP 3411068 A4 EP3411068 A4 EP 3411068A4 EP 17748163 A EP17748163 A EP 17748163A EP 3411068 A4 EP3411068 A4 EP 3411068A4
Authority
EP
European Patent Office
Prior art keywords
kdr
binding proteins
bispecific binding
bispecific
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17748163.7A
Other languages
German (de)
French (fr)
Other versions
EP3411068A2 (en
Inventor
Zhenping Zhu
Dan Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadmon Corp LLC
Original Assignee
Kadmon Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp LLC filed Critical Kadmon Corp LLC
Publication of EP3411068A2 publication Critical patent/EP3411068A2/en
Publication of EP3411068A4 publication Critical patent/EP3411068A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP17748163.7A 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr Withdrawn EP3411068A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
PCT/US2017/016230 WO2017136562A2 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Publications (2)

Publication Number Publication Date
EP3411068A2 EP3411068A2 (en) 2018-12-12
EP3411068A4 true EP3411068A4 (en) 2020-01-29

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17748163.7A Withdrawn EP3411068A4 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Country Status (5)

Country Link
EP (1) EP3411068A4 (en)
JP (1) JP2019506863A (en)
CN (1) CN109310755A (en)
EA (1) EA201891732A1 (en)
WO (1) WO2017136562A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42971A (en) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
JP2020522486A (en) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド Activatable anti-PDL1 antibody and method of using the same
JP7145895B2 (en) * 2017-09-01 2022-10-03 四川科倫博泰生物医薬股▲フン▼有限公司 recombinant bispecific antibody
KR102469248B1 (en) * 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. Bifunctional proteins with checkpoint inhibition for targeted therapy
CN111196856A (en) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 anti-HER 2/PD1 bispecific antibodies
CN111196855B (en) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 anti-EGFR/PD-1 bispecific antibodies
US11407832B2 (en) 2018-12-03 2022-08-09 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF
CN109776683B (en) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 Bispecific antibody and preparation method and application thereof
WO2020261093A1 (en) * 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN110563849B (en) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 anti-VEGF-anti-PD 1 bispecific antibody
CN110498857B (en) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 anti-VEGF-anti-PD 1 bispecific antibody
AU2019461286B2 (en) * 2019-08-09 2024-01-04 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-anti-PD1 bispecific antibody with new-type structure
CN110760517B (en) * 2019-10-09 2022-04-29 天津大学 Antagonistic PD-1 camel antibody analogue AP gene, protein and application
CN113563473A (en) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN113754772A (en) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 Bispecific antibody for resisting PDL1 XKDR
CN113754773A (en) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 Bispecific antibody for resisting PD1 XPDL 1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055996A2 (en) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Rho kinase inhibitors
WO2015109124A2 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051299A2 (en) * 2003-11-19 2005-06-09 Dyax Corp. Metalloproteinase-binding proteins
WO2008019061A2 (en) * 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
US7935345B2 (en) * 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
CA2819356C (en) * 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2625818T3 (en) * 2011-04-19 2017-07-20 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
HUE051954T2 (en) * 2011-11-28 2021-03-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
AU2013267267B2 (en) * 2012-05-31 2017-10-26 Genentech, Inc. Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
EP2903645A2 (en) * 2012-10-05 2015-08-12 Kadmon Corporation, LLC Treatment of ocular disorders
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055996A2 (en) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Rho kinase inhibitors
WO2015109124A2 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAN LU ET AL: "Abstract 572: A novel anti-PDL1 x anti-VEGFR2 bispecific antibody for enhanced antitumor immunity | Cancer Research", 16 April 2016 (2016-04-16), pages Abstract 572, XP055653955, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/76/14_Supplement/572.short> [retrieved on 20191218] *
ERIN LARKINS ET AL: "Regulatory Issues: FDA U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy", THE ONCOLOGIST, 2015, pages 1320 - 1325, XP055653942, Retrieved from the Internet <URL:http://theoncologist.alphamedpress.org/content/20/11/1320.long> [retrieved on 20191218] *
GEORGE W. SLEDGE: "Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?", JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 2, 10 January 2015 (2015-01-10), US, pages 133 - 135, XP055653932, ISSN: 0732-183X, DOI: 10.1200/JCO.2014.58.1298 *
ROLAND E. KONTERMANN ET AL: "Bispecific antibodies", DRUG DISCOVERY TODAY, vol. 20, no. 7, July 2015 (2015-07-01), AMSTERDAM, NL, pages 838 - 847, XP055251363, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2015.02.008 *

Also Published As

Publication number Publication date
WO2017136562A3 (en) 2017-09-28
CN109310755A (en) 2019-02-05
WO2017136562A2 (en) 2017-08-10
EP3411068A2 (en) 2018-12-12
JP2019506863A (en) 2019-03-14
EA201891732A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
EP3411068A4 (en) Bispecific binding proteins for pd-l1 and kdr
EP3452089A4 (en) Bispecific binding proteins and uses thereof
IL283115A (en) Bispecific cd33 and cd3 binding proteins
HK1252955A1 (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
EP3723803A4 (en) Anti-trem2 antibodies and related methods
EP3370769A4 (en) Antibodies specifically binding tim-3 and their uses
EP3489262A4 (en) Bispecific proteins and methods for preparing same
EP3512549A4 (en) Cd3 binding antibodies
EP3355920A4 (en) Pd-1 binding proteins and methods of use thereof
EP3471773A4 (en) Cd3 binding antibodies
IL260846B (en) Antigen binding proteins that bind pd-l1
EP3328895A4 (en) Anti-pd-1 antibodies and uses thereof
GB201805963D0 (en) PD-L1 Binding Affirmers and Uses Related Thereto
EP3352760A4 (en) Cd3 binding polypeptides
EP3218483A4 (en) Compounds and methods for the modulation of proteins
EP3316909A4 (en) Anti-ntb-a antibodies and related compositions and methods
EP3097122A4 (en) Binding proteins and methods of use thereof
EP3244727A4 (en) Insecticidal proteins and methods for their use
EP3140763A4 (en) Binding affinity prediction system and method
EP3304942A4 (en) Method and apparatus for sharing application
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
EP3302555A4 (en) Methods of using bispecific cd33 and cd3 binding proteins
EP3341021A4 (en) Anti-alk antibodies and methods for use thereof
EP3635100A4 (en) Compositions and methods for expressing otoferlin
EP3256163A4 (en) Methods and compositions for modulating lilr proteins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180831

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101ALI20191220BHEP

Ipc: A61K 39/395 20060101AFI20191220BHEP

Ipc: C07K 16/28 20060101ALI20191220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200808